Study shows combining gene therapy and radiation holds promise
A novel approach that combines gene therapy and radiation therapy for treating prostate cancer has shown promising results for its safety and effectiveness, according to Henry Ford Hospital researchers.
The study, published in this months edition of Cancer Research, shows that patients experienced no significant side effects when treated with gene therapy and radiation therapy. It also showed that the treatment lowered patients prostate-specific antigen (PSA) and eliminated the cancer in many of them.
PSA is a protein produced by the prostate. By measuring its level, doctors can monitor prostate cancer growth as well as the effectiveness of standard and investigational treatments.
All 15 patients enrolled in the study experienced significant declines in their PSA – from an average of 12 to below one – and 10 of them were cancer-free after one year. The patients had an aggressive form of prostate cancer that, if treated with standard radiation therapy alone, would likely recur and possibly spread.
While the results are encouraging, researchers say more research is needed and the novel treatment needs to be tested in a larger randomized clinical trial, which is planned for next year.
“Our belief is that gene therapy could make conventional cancer therapies such as radiation therapy more effective,” says Svend Freytag, Ph.D., division head of Henry Fords Radiation Oncology Research and lead author of the study.
The study is the first of its kind in the world to test the safety and effectiveness of a replication-competent virus in combination with radiation therapy. The replication-competent virus used in the treatment – the one associated with the common cold – has been shown to enhance the gene therapys effectiveness by spreading the gene therapy to nearby cells after it is injected into the prostate.
The virus kills the cancerous cells, but leaves normal ones undamaged. When combined with the gene therapy, it enhances the virus effect by rendering the malignant cells sensitive to radiation therapy.
An estimated 220,900 new cases of prostate cancer will be diagnosed this year, and nearly 29,000 men will die of it, according to the American Cancer Society. Prostate cancer is the second-leading cause of cancer death in men, after lung cancer.
All news from this category: Studies and Analyses
innovations-report maintains a wealth of in-depth studies and analyses from a variety of subject areas including business and finance, medicine and pharmacology, ecology and the environment, energy, communications and media, transportation, work, family and leisure.
Bringing atoms to a standstill: NIST miniaturizes laser cooling
It’s cool to be small. Scientists at the National Institute of Standards and Technology (NIST) have miniaturized the optical components required to cool atoms down to a few thousandths of…
Record-breaking laser link could help us test whether Einstein was right
Scientists from the International Centre for Radio Astronomy Research (ICRAR) and The University of Western Australia (UWA) have set a world record for the most stable transmission of a laser signal through…
Adaptive optics with cascading corrective elements
A cascaded dual deformable phase plate wavefront modulator enables direct AO integration with existing microscopes–doubling the aberration correction range and greatly improving image quality. Microscopy is the workhorse of contemporary…